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Abstract: The sequestration of Plasmodium falciparum–
infected red blood cells (irbcs) in the microvasculature of
organs is associated with severe disease; correspondingly,
the molecular basis of irbc adherence is an active area of
study. In contrast to P. falciparum, much less is known
a b o u ts e q u e s t r a t i o ni no t h e rPlasmodium parasites,
including those species that are used as models to study
severe malaria. Here, we review the cytoadherence
properties of irbcs of the rodent parasite Plasmodium
berghei ANKA, where schizonts demonstrate a clear
sequestration phenotype. Real-time in vivo imaging of
transgenic P. berghei parasites in rodents has revealed a
CD36-dependent sequestration in lungs and adipose
tissue. In the absence of direct orthologs of the P.
falciparum proteins that mediate binding to human CD36,
the P. berghei proteins and/or mechanisms of rodent
CD36 binding are as yet unknown. In addition to CD36-
dependent schizont sequestration, irbcs accumulate
during severe disease in different tissues, including the
brain. The role of sequestration is discussed in the context
of disease as are the general (dis)similarities of P. berghei
and P. falciparum sequestration.
Introduction
ErythrocytesinfectedwiththehumanmalariaparasitePlasmodium
falciparum are known to cytoadhere to endothelial cells lining blood
vessels, and this feature is associated with a number of features of
severe malaria pathology such as cerebral malaria (CM) and
pregnancy-associated malaria (PAM). This adherence of infected
red blood cells (irbcs) to host tissue, also known as sequestration,
occurs in small capillaries and post-capillary venules of specific
organs such as the brain and lungs. Sequestration has been
correlated with mechanical obstruction of blood flow in small blood
vessels and vascular endothelial cell activation, which may lead to
pathology [1–11]. As sequestration appears to be a signature of
severedisease,thefactorsthatmediateirbcadherencetoendothelial
cells have been the focus of numerous studies. This has resulted in
the identification of parasite proteins (ligands) and host endothelium
proteins (receptors, adhesins) that are directly involved in
sequestration [12–15]. It is anticipated that increased knowledge
on important features of sequestration, such as polymorphisms of
receptors and ligands and their interactions, tissue distribution,
affinity/avidity of binding, etc., will aid in the development of novel
strategies that either reduce disease or lead to complete protection,
for example through the development of vaccines or small molecule
inhibitors that inhibit sequestration [8,15–17].
The rodent parasite Plasmodium berghei is one of the most well-
employed models in malaria research, and this includes analyses
on the severe pathology associated with malaria infections. In
particular, P. berghei infections can induce a number of disease
states in rodents such as cerebral complications in several strains of
mice [18–23], pregnancy-associated pathology [24–26], and acute
lung injury [27,28]. To what extent these different pathologies
observed in laboratory animals are representative for human
pathology is a matter of debate and has been discussed in a
number of review papers [8,9,19,21,25,26,29–33]. Based on a
number of differences in clinical features of human cerebral
malaria (HCM) caused by P. falciparum and the cerebral pathology
of P. berghei infections in mice, the relevance of P. berghei for
understanding HCM has been brought into question. However, it
is evident that studies on so-called experimental cerebral malaria
(ECM) induced by P. berghei have provided insights into the critical
role that a variety of host immune factors play in inducing cerebral
pathology in mice. It has been argued that this knowledge may
indeed be relevant for understanding, at least in part, the
pathology associated with HCM, as the human condition itself is
likely to represent a spectrum of pathologies. Interestingly, in
contrast to the large number of studies on the role that various
immune factors play in producing or mitigating P. berghei ECM,
the role of P. berghei irbc sequestration in inducing these different
pathologies is less well understood. In some studies it has been
reported that P. berghei ECM is not correlated with extensive
schizont accumulation in small blood vessels of the brain; cerebral
complications in most ECM-susceptible mouse strains is more
often associated with an accumulation of immune cells in the brain
such as monocytes/macrophages, T cells, and neutrophils, and
sequestration of platelets [21,34–39]. In contrast, other studies
have reported that P. berghei ECM and PAM pathology is
associated with irbc accumulation in tissues such as the brain
and placenta [24,40–43]. In this paper, we review the available
knowledge and properties of P. berghei irbc sequestration and show
how recent advances in in vivo imaging technologies, which
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different organs of live mice, are being used to address issues of
sequestration and disease. An understanding of P. berghei
sequestration may help define and refine the relevance of rodent
infections in understanding the different features of sequestration
and pathology associated with human malaria (see Box 1 for the
terminology of P. berghei sequestration).
P. berghei ANKA Schizont-Infected Erythrocytes
Sequester
In P. falciparum, the absence of mature trophozoites, schizonts,
and developing gametocytes from the peripheral blood circulation
of humans is clear evidence for the sequestration of these stages
(Table 1). For various reasons, the detection of P. berghei
sequestration in mice by analyzing peripheral blood or tissue
histology is more complicated. Infections in mice with P. berghei
usually result in asynchronous parasite development, which in the
circulation of the host manifests itself as the simultaneous presence
of different parasite life cycle stages. Characterizing parasites in
peripheral blood is additionally confounded as several stages are
difficult to distinguish from each other, for example young
gametocytes and asexual trophozoites [44,45]. The asynchronous
course of infection in combination with the P. berghei schizont stage
of development being relatively short (i.e., only the last 4 hours of
the 22-hour erythrocytic cycle) may also hinder the detection of
schizonts in excised organ tissue by histology. P. berghei has a strong
preference for young red blood cells, reticulocytes, and these
become heavily invaded both early in an infection (when the
parasite tends only to infect reticulocytes) and also late in an
infection (when in response to malaria anemia the host produces
more reticulocytes). This often results in the presence of multiply
infected reticulocytes containing up to six to eight ring forms of the
parasites [46], and these cells can easily be confused with schizonts,
as the irbc now also has multiple nuclei. Moreover, in P. berghei
infections with higher parasite loads (parasitemias greater than 5%),
an increased number of schizonts are found in the blood circulation.
It is unknown whether the presence of circulating schizonts at high
parasite densities is due to the inability of schizonts to adhere to host
endothelium or is caused by factors that are related to the high
parasite loads. The particular characteristics of a P. berghei infection,
and the fact that cerebral complications are not associated with
extensive schizont accumulation in the brain, has led to the
common misconception that cytoadherence of P. berghei schizonts to
host microvasculature is not as pronounced as it is in P. falciparum.
Analysis of peripheral blood of experimentally synchronized
infections (see Box 2) has, however, clearly demonstrated that
schizonts of the P. berghei ANKA strain have a distinct sequestration
phenotype [35,44,47], resulting in the disappearance of all
schizogonic stages from the peripheral blood circulation. Synchro-
nized P. berghei infections in mice can be established by intravenous
injection of purified, fully mature schizonts [44,47]. In contrast to
most other Plasmodium species, viable and fully mature P. berghei
ANKA schizonts can easily be collected and purified from in vitro
cultures ([48]; Figure 1A). Injection of these schizonts into naı ¨ve
mice results in a rapid release of merozoites and an almost
simultaneous re-invasion of erythrocytes. In this way, synchronized
infections can be established with a stable parasitemia of 0.5%–3%
at 4 hours afterschizontinjectionwith thenewly invaded ring forms
developing into mature trophozoites within 16–18 hours. These
mature trophozoites then rapidly and reproducibly disappear from
the blood circulationwhere .90% of the parasitesthat demonstrate
nuclear division are absent from the peripheral blood, resulting in a
clear drop in parasitemia between 18 and 22 hours after schizont
injection (Figure 1A). At approximately 22 hours after inoculation,
the first newly invaded merozoites re-appear in the blood
circulation, and subsequent invasion of merozoites gives rise to a
second cycle of synchronized development [35,44]. Quantitative
analysis of the different blood stages in synchronized infections has
shown that ring stages and trophozoites (up to 16–18 hours old), as
well as immature and mature gametocytes, all remain in circulation
[44]. These observations conclusively demonstrate that P. berghei
ANKA schizonts are being retained in deep tissue and, moreover,
that this process is very tightly regulated, as sequestration of all
parasites starts with the onset of nuclear division. This absence of
schizonts in peripheral blood is not only observed in experimentally
induced, synchronized P. berghei ANKA infections but also in
asynchronous infections in mice, rats, and in the natural host
Grammomys surdaster [35]. Thus the sequestration of P. berghei
schizonts (i.e., their absence of the peripheral circulation) is
comparable to P. falciparum schizont sequestration. However, in P.
falciparum, in addition to schizonts, maturing trophozoites and
immature gametocytes are absent from peripheral blood, whereas
there is no evidence that these stages sequester in P. berghei infections
(Table 1). Further, in P. berghei infections, schizonts are more often
detected in peripheral blood at higher densities, whereas in P.
falciparum infections in humans this is rarely observed.
P. berghei ANKA Schizonts Accumulate in Lungs,
Adipose Tissue, and Spleen
A number of histological studies of animals infected with P.
berghei have failed to detect clear sequestration of irbcs, specifically
schizonts, in the brain microvasculature during ECM, raising the
question, if schizonts do not sequester in the brain, where are they
retained? In more recent studies in which schizonts were visualized
by real time imaging in live mice, it was revealed that the lungs,
adipose tissue, and the spleen are the major organs in which
schizonts specifically accumulate [35,43,49]. Infections with
transgenic P. berghei ANKA parasites, expressing the biolumines-
cent reporter-protein luciferase in conjunction with real time
Box 1. Plasmodium berghei Sequestration
Terminology
Cytoadherence of irbcs: The specific attachment of
irbcs to endothelial cells of blood capillaries and post-
capillary venules, mediated by host receptor(s) and
parasite ligand(s).
Sequestration of irbcs: An accumulation of irbcs in
organs as a result of specific interactions between parasite
ligands and host receptors expressed on the endothelium
of blood capillaries and post-capillary venules.
Parasite ligands: parasite factors expressed on the
surface of irbcs that mediate adherence to endothelial
cells of blood capillaries and post-capillary venules.
Host cell receptors (adhesions): molecules located on
the surface of endothelial cells of blood capillaries and
post-capillary venules that mediate sequestration of irbcs.
P. berghei CD36-mediated sequestration: Accumula-
tion of schizonts in organs as a result of specific
interactions between the host receptor CD36 and, as yet,
unknown putative parasite ligand(s).
P. berghei tissue accumulation/sequestration: Accu-
mulation of irbcs in organs as a result of interactions
between yet unknown parasite ligands and unknown host
receptors during malaria pathology (acute lung injury,
ECM, and PAM).
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these organs (see Box 3 for different transgenic parasite lines used
for in vivo imaging). By introducing the luciferase gene into the
genome under the control of a schizont-specific promoter (i.e., the
ama-1 promoter), only the schizont stage is made visible when
detecting bioluminescence signals, and this stage of the parasite is
specifically localized in lungs, adipose tissue, and the spleen
(Figure 2). No significant level of schizont accumulation could be
detected in other organs such as the brain, liver, and kidneys. This
pattern of schizont accumulation is not restricted to experimentally
induced, short-term synchronous infections; highly similar patterns
of schizont accumulation have been found during asynchronous
infections in both laboratory rodents and in G. surdaster [35]. In P.
falciparum, sequestration in organs has mainly been assessed by
examining post-mortem tissue obtained from individuals that died
from malaria. These studies have revealed that P. falciparum
schizonts sequester in differing amounts in tissues of a variety of
organs (Table 1). The lung and the spleen are recognized sites for
accumulation of P. falciparum schizonts, but adipose tissue
sequestration is less reported on. However, in several studies this
tissue has been identified as a site of P. falciparum schizont
sequestration [50–52,53]. What is less clear is whether the spleen
in P. berghei–infected mice is a site of sequestration or if schizonts
are trapped in the spleen as a result of selective clearance of irbcs
from the blood [54]. For Plasmodium vivax it has been proposed that
schizonts specifically adhere to barrier cells in the human spleen
allowing the parasite to escape spleen-clearance while simulta-
neously facilitating the rapid invasion of reticulocytes [55,56].
CD36 Is a Major Receptor for P. berghei ANKA
Schizont Sequestration in Lungs and Adipose
Tissue
Through the use of in vitro binding assays, a number of host
molecules that are expressed on the surface of endothelial cells have
been identified as playing a role in P. falciparum irbc adherence, such
as CD36, ICAM-1, PCAM-1/CD31, CR1, and chondroitin
sulphate A (CSA) (for review see [5,8,13]). Infected erythrocytes
from different P. falciparum isolates have quite different binding
Table 1. Sequestration Properties of Blood Stages of P. falciparum in Humans and P. berghei ANKA in Rodents.
P. berghei ANKA P. falciparum
Sequestration of blood stages
Stage of sequestration Schizonts (from the onset of nuclear division).
(Maturing trophozoites do NOT sequester and all gametocyte
stages appear to remain in circulation [24,44,47])
Maturing trophozoites, schizonts, and immature gametocytes.
Host cell receptors for
adherence
CD36.
Identified by in vivo analysis of sequestration in CD36
2/2 mice
using in vivo imaging [35].
Multiple receptors such as CD36, ICAM1, PCAM-1/CD31, CR1, CSA.
Identified using in vitro binding assays [5,8,13].
Parasite ligands Parasite ligands have not been identified. P. berghei does not
express proteins with homology to PfEMP1 but express proteins
belonging to other multi-gene families that are exported to the
red blood cell [66].
PfEMP1.
Identified using in vitro binding assays [63–65].
Sites of sequestration Abundant CD36-mediated schizont sequestration in lungs and
adipose tissue.
Accumulation of schizonts in the spleen [35,43].
Many different tissues, including the brain, lungs, spleen intestine,
skin, fat tissue, bone marrow, and skeletal and cardiac muscles
[53,105].
Organ sequestration has been assessed by examining post-mortem
tissue obtained from individuals that died from severe malaria.
Sequestration of blood stages associated with severe disease
Stage of sequestration Schizonts.
In addition, sequestration/accumulation of other asexual blood
stages [24,41–43].
See above.
In addition, evidence has been presented for sequestration of young
trophozoites during severe disease [105,106].
Host cell receptors CD36 for schizonts (see above). Receptors for other blood
stages have not been identified.
See above.
During severe disease the distribution of schizont sequestration may
change as a result of changes in expression of host cell receptors
[107–110].
Parasite ligands See above.
No putative ligand identified for CD36-mediated sequestration
nor any other ligand that may be involved in sequestration/
accumulation of other blood stages during severe disease.
See above.
During severe disease and pregnancy associated malaria selection
favors parasites expressing specific variants of PfEMP1 [108,111–
113].
Sites of sequestration CD36-mediated schizont sequestration in lungs and adipose
tissue [35].
Accumulation of schizonts in the spleen [35].
Accumulation of irbcs in different tissues including the brain
and placenta of pregnant mice [24,26,41–43].
See above.
Abundant sequestration in brain tissue in many patients that died
from cerebral complications and in the placenta of pregnant women
[15,114,115].
doi:10.1371/journal.ppat.1001032.t001
Box 2. P. berghei ANKA Infections in Rodents
Synchronized infections: Experimentally induced infec-
tions by intravenous injection of mature schizonts
resulting in the synchronized development of asexual
blood stage parasites for up to two developmental cycles.
Asynchronous infections: Infections, usually estab-
lished by an intra-peritoneal injection of 10
4–10
5 irbcs
that exhibit all parasite developmental stages in the blood
simultaneously. These infections result in ECM pathology
in ECM-susceptible mice, usually on day 6–8 after infection.
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[8,57,58]. Most P. falciparum isolates, however, demonstrate a
capacity to bind to CD36 [58], and CD36 and CSA are the only
two receptors that maintain a stable stationary adherence to irbcs.
The application of in vivo imaging techniques in laboratory
animals that either express or lack CD36 revealed that CD36 also
has a major role in P. berghei schizont sequestration, specifically in
adipose tissue and lungs (Figure 1; [35]). In animals deficient in
expressing CD36, the sequestration of schizonts in both the lungs
and adipose tissue was strongly reduced. This was the first report, in
any Plasmodium species, that analyzed irbc sequestration to host cell
receptors in a living animal, and in real time through the course of
Figure 1. P. berghei ANKA asexual blood stage development and expression of proteins in mature schizonts. (A) In vivo and in vitro
development of rings, trophozoites, and schizonts during one cycle of synchronized development. In mice, rings and trophozoites do not sequester
but schizonts disappear from the peripheral circulation (upper graph). In vitro schizogony takes place between 18 and 24 hours after invasion of the
red blood cell (lower graph). The arrow indicates a multiply infected red blood cell containing three trophozoite-stage parasites; above this cell isa
20-hour schizont (graphs adapted from [44] and [35]. (B) Live mature schizonts of two transgenic lines expressing two different fluorescently tagged
PIR proteins either tagged with GFP (eG; PB200064.00.0) or mCherry (mC; PB200026.00.0). These proteins are exported into the cytoplasm of the
erythrocyte nucleus stained with Hoechst (H; blue), red blood cell membrane surface protein stained in mC parasites (TER-FITC; green) (J. Braks and B.
Franke-Fayard, unpublished data). (C) Live mature schizonts that express GFP and mCherry in the cytoplasm of the merozoites (J. Braks and B. Franke-
Fayard, unpublished data).
doi:10.1371/journal.ppat.1001032.g001
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endothelium of brain capillaries and post-capillary venules [59,60],
but there are high levels of CD36 expression on endothelium of
lungs and adipose tissue [60,61]. This sequestration is clearly
consistentwithschizont sequestrationinthelungsand adipose tissue
and absence of sequestration in the brain. Compared to the lungs or
adiposetissue,P.bergheischizontaccumulationinthe spleendoesnot
decrease in the absence of CD36 (Figure 1; [35]), and therefore
accumulation in this organ results either from ‘‘nonspecific
trapping’’ of schizonts or from interactions of schizonts to
alternative host receptors. The role of CD36 as a major receptor
for the adherence of P. falciparum irbcs to endothelial cells is well
established and this receptor is known to be abundantly expressed
on the surface of capillary endothelial cells in human adipose tissue
[60,61]. Surprisingly, however, no detailed studies have been
conducted in human malaria on the extent and importance of
adipose tissue. The observations of CD36-mediated sequestration of
P. berghei and binding of irbcs of Plasmodium chabaudi to CD36 [62]
suggest that binding to CD36 is an ‘‘ancient’’ feature of the
Plasmodium genus. It would also indicate that rodent parasites
modulate the surface of irbcs through the active export of proteins
that contain as yet unidentified and potentially conserved receptor-
binding domains (see below).
Parasite Ligands Involved in CD36-Mediated
Sequestration of P. berghei ANKA Schizonts Are
Still Unknown
The variant protein PfEMP1 plays a major role in adherence of
P. falciparum irbcs to different endothelial host receptors. This
protein is encoded by a family of approximately 60 (var) genes
within each parasite genome, and the expression of these proteins
is mutually exclusive with only one PfEMP1 expressed on the
surface of the irbc at any one time (for reviews see [63]). The
extracellular region of this protein contains multiple adhesion
domains, such as DBL domains, named for their homology to the
EBL domains involved in red blood cell invasion, and one to two
cysteine-rich interdomain regions (CIDRs). The binding domains
for several host receptors have been mapped to the various DBL
and CIDR domains with the CIDR1a domain mediating binding
to CD36 [64,65]. The P. berghei genome does not contain genes
with homology to the var genes [66] and, as yet, no other P. berghei
proteins have been identified that may bind to CD36. Hidden
Markov Model (HMM) building using P. falciparum CIDR and
DBL domains, followed by searches of all predicted P. berghei
proteins available in PlasmoDB (release 6.3), have not provided
evidence for the presence of proteins containing these domains (J.
Fonager, unpublished data). Indeed, the only proteins in rodent
malaria parasites that have been identified as being either
expressed close to or on the irbc surface are members of the
variant multigene family ‘‘Plasmodium interspersed repeats’’ (PIRs)
[67]. These genes are shared between human, rodent, and monkey
malaria species [68–71]. It is, however, questionable whether these
proteins mediate adherence of schizonts to CD36. PIR proteins
are also expressed in the human parasite P. vivax [56,72], and
although it has been suggested that sequestration of P. vivax irbcs
might occur in the spleen and in other organs such as the lung
during severe disease [55,73,74], there is no evidence for
adherence of the schizonts stage to CD36 since in most infections
schizonts can be found in the peripheral circulation. In addition, it
is also not clear yet whether the putative extracellular domains of
these proteins are indeed exposed on the outer erythrocyte
membrane [56]. Analysis of the localization of two GFP- and
mCherry-tagged P. berghei members of this family (PB200064.00.0;
PB200026.00.0) showed that these proteins are exported into the
host erythrocyte, but we have been unable to demonstrate an
exposed surface location of these proteins ([75]; B.F. and J.
Fonager, unpublished data; Figure 1B). Various other multigene
families exist in P. berghei that have features of proteins exported
into the host erythrocyte and which may modify the surface
membrane of the irbc. For example, P. berghei orthologs to genes
encoding proteins of the PYST-A and PYST-B gene families
contain either predicted signal peptides only (PYST-A) or
predicted signal peptide and the Plasmodium export (PEXEL) motif
(PYST-B) [69,76] that target proteins out of the parasite into the
red blood cell, and we have indeed found that PYST-A proteins
are exported into the cytoplasm of the erythrocyte (J. Braks,
unpublished data). It is, however, possible that CD36-mediated
schizont sequestration in P. berghei does not depend on the
Box 3. Different Luciferase-Expressing P.
berghei ANKA Parasites That Are Used for
Real Time Imaging of Parasite Distribution in
Live Mice
P. berghei ANKA: Luciferase expression con-
trolled by the schizont-specific ama1-promoter,
RMgm-30 and 32
*
Analysis of sequestration of schizonts in synchronized
infections. Bioluminescence of sequestered schizonts
(also newly invaded ring forms show luminescence
resulting from carry over of luciferase from the mature
schizont stage).
P. berghei ANKA: Luciferase expression con-
trolled by the constitutive ‘‘all stages’’ eef1a-
promoter, RMgm-28 and 29
*
Analysis of tissue distribution of irbcs. All stages are
bioluminescent. These lines produce gametocytes that
can complicate tissue distribution analyses as a result of
high luminescence signals derived from circulating
female gametocytes.
P. berghei ANKA: Luciferase expression con-
trolled by the constitutive ‘‘all stages’’ eef1a-
promoter, RMgm-333
*
Analysis of tissue distribution of asexual blood stages.
All stages are bioluminescent. This line does not
produce gametocytes.
P. berghei K173: Luciferase expression controlled
by the schizont-specific ama1-promoter, RMgm-
375
*
Bioluminescence of schizonts (also newly invaded ring
forms show luminescence resulting from carry over of
luciferase from the mature schizont stage). Schizonts of
this line do not sequester and this line does not
produce gametocytes.
P. berghei K173: Luciferase expression controlled
by the schizont-specific ama1-promoter, RMgm-
380
*
All stages are bioluminescent. Schizonts of this line do
not sequester and this line does not produce
gametocytes.
*These lines have been described in the RMgm-
database (http://www.pberghei.eu/) of P. berghei
mutants.
–
–
–
–
–
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result of changes in the red blood cell membrane itself. For
instance, the intracellular parasite may cause a disruption in the
asymmetric distribution of molecules in the irbc membrane
bilayer, for example, phosphatidylserine (PS). This molecule, PS,
is localized on the inner leaflet of the lipid bilayer and can become
‘‘flipped’’ on to the outer surface of the erythrocyte under some
physiological conditions. It is known that PS is able to interact
directly with CD36 [77–79], and evidence has been found that
adherence of P. falciparum irbcs to CD36 is in part mediated by
surface-exposed PS on irbcs. Similarly, it has been proposed that
P. falciparum is able to modify the red blood cell protein band 3,
and such modifications permit irbc adherence to CD36 [13]; the
parasite proteins responsible for this alteration of band 3 remain to
be characterized. Clearly, further research is required to unravel
the mechanisms and proteins involved that mediate CD36-
sequestration of P. berghei schizonts. Leaving aside issues relating
to cerebral complications, a greater understanding of the cellular
and tissue distribution of CD36 in the host as well as the
mechanisms by which this receptor is recognized by P. berghei
parasites is likely to shed light on what are likely to be very similar
processes in CD36-mediated sequestration of P. falciparum irbcs.
Is CD36-Mediated Sequestration of Schizonts
Associated with Cerebral Complications in Mice?
Several studies report evidence indicating that CD36-mediated
sequestration of P. berghei is not directly associated with cerebral
pathology. Firstly, infections in CD36-deficient mice exhibit no
sequestration in lungs and adipose tissue but still develop ECM
[27,35]. In addition, a P. berghei ANKA mutant, generated by a
single gene deletion, is found not to induce cerebral complications
but shows a completely normal distribution of CD36-mediated
schizont sequestration [43]. Lastly, ECM-susceptible mice infected
with a laboratory line of the K173 strain of P. berghei parasites that
lack schizont sequestration do develop ECM (Figure 2; [80,81]).
The absence of schizont sequestration can most likely be explained
by the laboratory history of this line; it has been kept for more than
20 years in mice by mechanical blood passage and has completely
lost gametocyte production and schizont sequestration, and its
Figure 2. Imaging of transgenic P. berghei ANKA parasites in vivo and ex vivo. CD36-mediated sequestration of schizonts in adipose tissue
and lungs (adapted from PNAS, 2005 [35]). (A, B) Distribution of transgenic P. berghei ANKA parasites, expressing GFP::luciferase fusion protein (ama-1
promoter, see Box 3). Parasites are visible in lungs, spleen, and adipose tissue in wild-type mice, and principally in the blood circulation and
accumulated in the spleen in CD36 knock-out mice. In wild-type mice infected with a non-sequestering K173 line, schizonts are also mainly found in
the peripheral blood circulation and accumulated in the spleen (1: adipose tissue; 2: spleen; 3 liver; 4: lungs; 5: heart; 6: kidney; 7: brain). (C)
Sequestration of transgenic P. berghei ANKA parasites in microvasculature of adipose tissue (upper panel with under phase contrast and lower panel
with GFP-positive schizonts indicated by arrows).
doi:10.1371/journal.ppat.1001032.g002
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subtelomeric genes and repeat elements ([82,83]; J. Fonager,
unpublished data). This line has frequently been used to study P.
berghei ECM [80,81], supporting the other published observations
that schizont sequestration is not a prerequisite for P. berghei ECM.
Interestingly, parasites of another laboratory line of the K173
strain have been shown not to induce cerebral complications
[84,85]. The sequestration pattern of the schizonts of this line is
unknown, but these observations show that the capacity to induce
ECM is not a stable feature of P. berghei strains. This has also been
shown by analyzing clones of the ANKA strain that showed
differences in their abilities to induce ECM [23].
The significance of studies examining P. berghei ECM for
understanding human pathology has been brought into question,
mainly because a number of differences exist in cerebral pathology
between mice and humans, and also because of the observation
that there appears to be a close association between the level of
sequestration in the brain and HCM [33]. Therefore, the lack of
an association between CD36-mediated schizonts sequestration
and cerebral complications in P. berghei–infected mice appears to
challenge the relevance of P. berghei as a model of HCM [33].
However, the contribution of P. falciparum CD36-mediated irbc
adherence to human pathology is also not resolved. For example,
in human infections, variation in irbc binding to CD36 has been
correlated with either no effect, an increase, or a decrease in
disease severity [86–91]. As expression of CD36 on endothelium
in the brain is virtually absent, direct adherence of irbcs to
endothelial CD36 is unlikely to account for significant cerebral
sequestration. On the other hand, CD36 is highly expressed on
monocytes, macrophages, and platelets, and it has been proposed
that irbc sequestration in the brain may be mediated via irbc
attachment to CD36 of sequestered platelets that act as a bridge
between endothelial cells and irbcs [92,93]. Severity of disease has
also been attributed to platelet-mediated clumping of P. falciparum
irbcs [90]. It has been argued that CD36 may also have a
beneficial role in that the innate immune response may be
modulated by irbc binding to CD36 on macrophages, resulting in
non-opsonic phagocytosis [59,94,95]. A beneficial effect of CD36
expression on macrophages and dendritic cells resulting in reduced
virulence has also been observed in P. berghei infections [96].
Moreover, adherence to CD36 expressed in microvascular
endothelium of the skin and adipose tissue may reduce pathology,
as it directs irbcs away from more vital and potentially life
threatening sites such as the cerebral microvasculature. Although a
clear association between sequestered irbcs and HCM exists in P.
falciparum, additional investigations are required to unravel the role
that CD36-dependent cytoadherence has for either pathogenesis
or protection from disease in P. falciparum infections.
Evidence for CD36-Independent Sequestration of
P. berghei ANKA
The distribution of P. berghei schizonts in the organs in mice has
principally been analyzed by the imaging of schizonts in short-
term synchronous infections in living animals. Such patterns are
not likely to identify alterations in sequestration due to changes in
expression of other putative endothelial receptors, something that
is likely to occur after the initial stage of an infection. For example,
it has been shown that inflammatory markers and adhesins such as
ICAM-1 become up-regulated on endothelium of the brain and
lung microvasculature during P. berghei ECM [27,97,98]. When
the distribution of P. berghei schizonts was imaged in live mice
during prolonged infections, no major changes in the organ
distribution of schizont sequestration were observed [35]. This
would suggest that CD36 remains the major binding receptor for
schizonts and that there is no obvious switch in schizont adherence
phenotype during an infection. Several recent studies have shown,
however, that severe disease complications such as ECM and
PAM are associated with a distinct increase of irbcs accumulating
in different tissues, including the brain and placenta [24,41–43],
indicating that additional factors play a role in irbc sequestration
after the initial phase of a P. berghei infection. It has been shown by
in vivo imaging that the timing of this irbc accumulation in the
brain coincides with the development of cerebral complications,
and mice protected from cerebral complications do not show a
similar increase of irbc sequestration in the brain (Figure 3). In
these studies the parasites used for in vivo imaging of sequestered
irbcs expressed luciferase under the control of the constitutive P.
berghei eef1a promoter (Box 3), and therefore it is not possible to
discriminate between sequestered schizonts and other blood stage
parasites such as rings and trophozoites. Whether this tissue
accumulation of irbcs during severe disease is mediated by specific
interactions between parasite ligands and endothelial receptors
brain capillaries and post-capillary venules or is the result of other
mechanisms (see above) of irbc trapping in small blood capillaries
is unknown. For example, P. berghei irbcs have been observed to
attach to the surface of endothelium-adherent monocytes/
macrophages [21]. Evidence has also been found for irbc
accumulation in capillaries as a result of adherence to sequestered
platelets [37]. As increased mononuclear cell [34] and platelet
sequestration [37,39] is observed in the brain vessels of mice
during ECM, monocyte/platelet-trapped irbcs may account, at
least in part, for parasites present in the brain vasculature. On the
other hand, P. berghei irbcs have been observed in close contact
with the microvascular endothelium [40], indicating that irbcs
may directly adhere to endothelial cells. Further analysis is
required to provide an insight into both the amounts of parasites
Figure 3. Imaging of transgenic P. berghei ANKA parasites in
brains of mice ex vivo. Matched sets of experiments with P. berghei
ANKA infections in ECM-sensitive mice (i.e., wild-type mice) or knock-out
mice (i.e., IP10
2/2). Knock-out mice do not develop cerebral pathology
and this corresponds to a strong reduction in irbc accumulation as
compared to infections in wild-type mice (adapted from [41]). Similar
examples of a lack of irbc accumulation can be observed in the brains of
mice treated with antibodies against host molecules (e.g., anti-LTb mAB
and anti-CD25 mAB; see [42,104]). Parasites express GFP::luciferase
fusion protein under the control of the eef1a promoter, see Box 3). Also,
mice infected with a P. berghei ANKA mutant that has had the gene
encoding plasmepsin 4 removed do not develop cerebral complica-
tions, and again there is a strong reduction of irbc accumulation in the
brain of these infected animals (adapted from [43]).
doi:10.1371/journal.ppat.1001032.g003
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parasite that is found in tissue during severe disease. The
generation of transgenic P. berghei parasites expressing different
fluorescent reporter proteins (e.g., GFP and mCherry; see
Figure 1C) now offers the possibility of directly visualizing
interactions between host cells and irbcs in the brain of living
mice by, for example, using multiphoton microscopy to perform
intravital imaging [99–102]. An understanding of the mechanisms
of CD36-independent sequestration may help to define the
contribution of other host receptors to irbc adherence and the
relationship with induction of pathology.
In addition to CD36-mediated schizont sequestration and irbc
sequestration during ECM, evidence has also been found for
adherence of P. berghei irbcs to CSA present on the surface of
syncytiotrophoblasts in the placenta of pregnant mice. Specifically,
irbcs in pregnancy-induced recrudescent infections showed an
enhancement of in vitro adherence to placenta tissue with a
marked specificity for CSA [26]. As with CD36 sequestration, the
P. berghei ligands mediating adherence to CSA are also unknown.
Conclusion
Revealing where and when P. berghei sequesters in a living host,
by real time imaging of transgenic parasites, has opened up
exciting possibilities into research looking at sequestration and the
contribution this has to different aspects of malarial disease.
Schizonts of P. berghei sequester in the body of living animals in
distinct locations, and this appears to be related to the expression
of host CD36 with abundant sequestration in adipose tissue and
lungs. CD36-mediated schizont sequestration is not observed in
the brain, but evidence has been presented for a CD36-
independent accumulation of irbcs in different tissues during
severe disease, including the brain. The characterization and the
genetic modification of P. berghei ligands involved in binding to the
different host receptors might offer novel possibilities in the
development of small-animal models for analysis of sequestration
properties of P. falciparum ligands that have hitherto only been
examined in vitro. This could be performed by, for example,
substituting P. berghei ligands with P. falciparum PfEMP-1 proteins or
domains. Using in vivo imaging in conjunction with such
‘‘falciparumized’’ P. berghei parasites in mice expressing human
receptors (e.g., human ICAM-1; [103]) may create an in vivo
screening system for testing inhibitors that block P. falciparum
sequestration. Despite clear differences between the rodent model
and human infections, we believe enough similarities remain that
justify further studies on P. berghei sequestration for obtaining more
insight into how the malaria parasite uses sequestration to survive
inside the host, how this may provoke disease, and how
interventions may work.
Acknowledgments
We would like to very much thank Nick White and Eleanor Riley for
reading our manuscript and are grateful for their very useful comments and
suggestions. We would like to thank Chris Engwerda for stimulating
discussions on the nature and consequences of P. berghei sequestration that,
in part, provoked us into writing this review and for his subsequent
comments on this manuscript.
References
1. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW (2007) Malaria in
pregnancy: pathogenesis and immunity. Lancet Infect Dis 7: 105–117.
2. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, et al. (2007)
Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7:
93–104.
3. Beeson JG, Duffy PE (2005) The immunology and pathogenesis of malaria
during pregnancy. Curr Top Microbiol Immunol 297: 187–227.
4. Mackintosh CL, Beeson JG, Marsh K (2004) Clinical features and pathogenesis
of severe malaria. Trends Parasitol 20: 597–603.
5. Rasti N, Wahlgren M, Chen Q (2004) Molecular aspects of malaria
pathogenesis. FEMS Immunol Med Microbiol 41: 9–26.
6. Clark IA, Alleva LM, Mills AC, Cowden WB (2004) Pathogenesis of malaria
and clinically similar conditions. Clin Microbiol Rev 17: 509–39, table.
7. van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE (2006) A
unified hypothesis for the genesis of cerebral malaria: sequestration,
inflammation and hemostasis leading to microcirculatory dysfunction. Trends
Parasitol 22: 503–508.
8. Miller LH, Baruch DI, Marsh K, Doumbo OK (2002) The pathogenic basis of
malaria. Nature 415: 673–679.
9. Idro R, Jenkins NE, Newton CR (2005) Pathogenesis, clinical features, and
neurological outcome of cerebral malaria. Lancet Neurol 4: 827–840.
10. Schofield L, Grau GE (2005) Immunological processes in malaria pathogenesis.
Nat Rev Immunol 5: 722–735.
11. Mishra SK, Newton CR (2009) Diagnosis and management of the neurological
complications of falciparum malaria. Nat Rev Neurol 5: 189–198.
12. Kraemer SM, Smith JD (2006) A family affair: var genes, PfEMP1 binding, and
malaria disease. Curr Opin Microbiol 9: 374–380.
13. Sherman IW, Eda S, Winograd E (2003) Cytoadherence and sequestration in
Plasmodium falciparum: defining the ties that bind. Microbes Infect 5:
897–909.
14. Deitsch KW, Hviid L (2004) Variant surface antigens, virulence genes and the
pathogenesis of malaria. Trends Parasitol 20: 562–566.
15. Gamain B, Smith JD, Viebig NK, Gysin J, Scherf A (2007) Pregnancy-
associated malaria: parasite binding, natural immunity and vaccine develop-
ment. Int J Parasitol 37: 273–283.
16. Rowe JA, Claessens A, Corrigan RA, Arman M (2009) Adhesion of
Plasmodium falciparum-infected erythrocytes to human cells: molecular
mechanisms and therapeutic implications. Expert Rev Mol Med 11: e16.
17. Hviid L (2010) The role of Plasmodium falciparum variant surface antigens in
protective immunity and vaccine development. Hum Vaccin 6: 84–89.
18. Lamb TJ, Brown DE, Potocnik AJ, Langhorne J (2006) Insights into the
immunopathogenesis of malaria using mouse models. Expert Rev Mol Med 8:
1–22.
19. Engwerda C, Belnoue E, Gruner AC, Renia L (2005) Experimental models of
cerebral malaria. Curr Top Microbiol Immunol 297: 103–143.
20. de Souza JB, Riley EM (2002) Cerebral malaria: the contribution of studies in
animal models to our understanding of immunopathogenesis. Microbes Infect
4: 291–300.
21. Martins YC, Smith MJ, Pelajo-Machado M, Werneck GL, Lenzi HL, et al.
(2009) Characterization of cerebral malaria in the outbred Swiss Webster
mouse infected by Plasmodium berghei ANKA. Int J Exp Pathol 90: 119–130.
22. Randall LM, Amante FH, McSweeney KA, Zhou Y, Stanley AC, et al. (2008)
Common strategies to prevent and modulate experimental cerebral malaria in
mouse strains with different susceptibilities. Infect Immun 76: 3312–3320.
23. Amani V, Boubou MI, Pied S, Marussig M, Walliker D, et al. (1998) Cloned
lines of Plasmodium berghei ANKA differ in their abilities to induce
experimental cerebral malaria. Infect Immun 66: 4093–4099.
24. Neres R, Marinho CR, Goncalves LA, Catarino MB, Penha-Goncalves C
(2008) Pregnancy outcome and placenta pathology in Plasmodium berghei
ANKA infected mice reproduce the pathogenesis of severe malaria in pregnant
women. PLoS ONE 3: e1608. doi:10.1371/journal.pone.0001608.
25. Megnekou R, Hviid L, Staalsoe T (2009) Variant-specific immunity to
Plasmodium berghei in pregnant mice. Infect Immun 77: 1827–1834.
26. Marinho CR, Neres R, Epiphanio S, Goncalves LA, Catarino MB, et al. (2009)
Recrudescent Plasmodium berghei from pregnant mice displays enhanced
binding to the placenta and induces protection in multigravida. PLoS ONE 4:
e5630. doi:10.1371/journal.pone.0005630.
27. Lovegrove FE, Gharib SA, Pena-Castillo L, Patel SN, Ruzinski JT, et al. (2008)
Parasite burden and CD36-mediated sequestration are determinants of acute
lung injury in an experimental malaria model. PLoS Pathog 4: e1000068.
doi:10.1371/journal.ppat.1000068.
28. Van den Steen PE, Geurts N, Deroost K, Van AI, Verhenne S, et al. (2010)
Immunopathology and dexamethasone therapy in a new model for malaria-
associated acute respiratory distress syndrome. Am J Respir Crit Care Med
181: 957–968.
29. Hunt NH, Grau GE (2003) Cytokines: accelerators and brakes in the
pathogenesis of cerebral malaria. Trends Immunol 24: 491–499.
30. Poovassery JS, Sarr D, Smith G, Nagy T, Moore JM (2009) Malaria-induced
murine pregnancy failure: distinct roles for IFN-gamma and TNF. J Immunol
183: 5342–5349.
31. de SBJ, Hafalla JC, Riley EM, Couper KN (2009) Cerebral malaria: why
experimental murine models are required to understand the pathogenesis of
disease. Parasitology. pp 1–18.
32. Davison BB, Cogswell FB, Baskin GB, Falkenstein KP, Henson EW, et al.
(2000) Placental changes associated with fetal outcome in the Plasmodium
PLoS Pathogens | www.plospathogens.org 8 September 2010 | Volume 6 | Issue 9 | e1001032coatneyi/rhesus monkey model of malaria in pregnancy. Am J Trop Med Hyg
63: 158–173.
33. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP (2009) The
murine cerebral malaria phenomenon. Trends Parasitol 26: 11–15.
34. Renia L, Potter SM, Mauduit M, Rosa DS, Kayibanda M, Deschemin JC,
Snounou G, Gruner AC (2006) Pathogenic T cells in cerebral malaria.
Int J Parasitol 36: 547–554.
35. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Buscher P, et al.
(2005) Murine malaria parasite sequestration: CD36 is the major receptor, but
cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci U S A 102:
11468–11473.
36. Lou J, Lucas R, Grau GE (2001) Pathogenesis of cerebral malaria: recent
experimental data and possible applications for humans. Clin Microbiol Rev
14: 810–20, table.
37. Combes V, Coltel N, Faille D, Wassmer SC, Grau GE (2006) Cerebral
malaria: role of microparticles and platelets in alterations of the blood-brain
barrier. Int J Parasitol 36: 541–546.
38. Grau GE, Bieler G, Pointaire P, De KS, Tacchini-Cotier F, et al. (1990)
Significance of cytokine production and adhesion molecules in malarial
immunopathology. Immunol Lett 25: 189–194.
39. Sun G, Chang WL, Li J, Berney SM, Kimpel D, et al. (2003) Inhibition of
platelet adherence to brain microvasculature protects against severe Plasmo-
dium berghei malaria. Infect Immun 71: 6553–6561.
40. Hearn J, Rayment N, Landon DN, Katz DR, de Souza JB (2000)
Immunopathology of cerebral malaria: morphological evidence of parasite
sequestration in murine brain microvasculature. Infect Immun 68: 5364–5376.
41. Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, et al. (2009) IP-
10-mediated T cell homing promotes cerebral inflammation over splenic
immunity to malaria infection. PLoS Pathog 5: e1000369. doi:10.1371/
journal.ppat.1000369.
42. Amante FH, Stanley AC, Randall LM, Zhou Y, Haque A, et al. (2007) A role
for natural regulatory T cells in the pathogenesis of experimental cerebral
malaria. Am J Pathol 171: 548–559.
43. Spaccapelo R, Janse CJ, Caterbi S, Franke-Fayard B, Bonilla JA, et al. (2010)
Plasmepsin 4-deficient Plasmodium berghei are virulence attenuated and
induce protective immunity against experimental malaria. Am J Pathol 176:
205–217.
44. Mons B, Janse CJ, Boorsma EG, Van der Kaay HJ (1985) Synchronized
erythrocytic schizogony and gametocytogenesis of Plasmodium berghei in vivo
and in vitro. Parasitology 91(Pt 3): 423–430.
45. Janse CJ, Waters AP (2004) Sexual development of malaria parasites. In
Waters AP, Janse CJ, eds. Malaria parasites: genomes and molecular biology.
Norwich: Caister Academic Press. pp 445–475.
46. Landau I, Boulard Y (1978) Rodent malaria. In Killick-Kendrick R, Peters W,
eds. London: Academic Press. pp 53–84.
47. Janse CJ, Waters AP (1995) Plasmodium berghei: the application of cultivation
and purification techniques to molecular studies of malaria parasites. Parasitol
Today 11: 138–143.
48. Janse CJ, Ramesar J, Waters AP (2006) High-efficiency transfection and drug
selection of genetically transformed blood stages of the rodent malaria parasite
Plasmodium berghei. Nat Protoc 1: 346–356.
49. Franke-Fayard B, Waters AP, Janse CJ (2006) Real-time in vivo imaging of
transgenic bioluminescent blood stages of rodent malaria parasites in mice. Nat
Protoc 1: 476–485.
50. Miller LH (1969) Distribution of mature trophozoites and schizonts of
Plasmodium falciparum in the organs of Aotus trivirgatus, the night monkey.
Am J Trop Med Hyg 18: 860–865.
51. Miller LH, Fremount HN, Luse SA (1971) Deep vascular schizogony of
Plasmodium knowlesi in Macaca mulatta. Distribution in organs and
ultrastructure of parasitized red cells. Am J Trop Med Hyg 20: 816–824.
52. Wilairatana P, Riganti M, Puchadapirom P, Punpoowong B, Vannaphan S,
et al. (2000) Prognostic significance of skin and subcutaneous fat sequestration
of parasites in severe falciparum malaria. Southeast Asian J Trop Med Public
Health 31: 203–212.
53. Haldar K, Murphy SC, Milner DA, Taylor TE (2007) Malaria: mechanisms of
erythrocytic infection and pathological correlates of severe disease. Annu Rev
Pathol 2: 217–249.
54. Engwerda CR, Beattie L, Amante FH (2005) The importance of the spleen in
malaria. Trends Parasitol 21: 75–80.
55. del Portillo HA, Lanzer M, Rodriguez-Malaga S, Zavala F, Fernandez-
Becerra C (2004) Variant genes and the spleen in Plasmodium vivax malaria.
Int J Parasitol 34: 1547–1554.
56. Fernandez-Becerra C, Yamamoto MM, Vencio RZ, Lacerda M, Rosanas-
Urgell A, et al. (2009) Plasmodium vivax and the importance of the
subtelomeric multigene vir superfamily. Trends Parasitol 25: 44–51.
57. Beeson JG, Brown GV, Molyneux ME, Mhango C, Dzinjalamala F, et al.
(1999) Plasmodium falciparum isolates from infected pregnant women and
children are associated with distinct adhesive and antigenic properties. J Infect
Dis 180: 464–472.
58. Newbold C, Warn P, Black G, Berendt A, Craig A, et al. (1997) Receptor-
specific adhesion and clinical disease in Plasmodium falciparum. Am J Trop
Med Hyg 57: 389–398.
59. Patel SN, Serghides L, Smith TG, Febbraio M, Silverstein RL, et al. (2004)
CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythro-
cytes by rodent macrophages. J Infect Dis 189: 204–213.
60. Greenwalt DE, Scheck SH, Rhinehart-Jones T (1995) Heart CD36 expression
is increased in murine models of diabetes and in mice fed a high fat diet. J Clin
Invest 96: 1382–1388.
61. Febbraio M, Hajjar DP, Silverstein RL (2001) CD36: a class B scavenger
receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid
metabolism. J Clin Invest 108: 785–791.
62. Mota MM, Jarra W, Hirst E, Patnaik PK, Holder AA (2000) Plasmodium
chabaudi-infected erythrocytes adhere to CD36 and bind to microvascular
endothelial cells in an organ-specific way. Infect Immun 68: 4135–4144.
63. Scherf A, Pouvelle B, Buffet PA, Gysin J (2001) Molecular mechanisms of
Plasmodium falciparum placental adhesion. Cell Microbiol 3: 125–131.
64. Smith JD, Kyes S, Craig AG, Fagan T, Hudson-Taylor D, et al. (1998) Analysis
of adhesive domains from the A4VAR Plasmodium falciparum erythrocyte
membrane protein-1 identifies a CD36 binding domain. Mol Biochem
Parasitol 97: 133–148.
65. Klein MM, Gittis AG, Su HP, Makobongo MO, Moore JM, et al. (2008) The
cysteine-rich interdomain region from the highly variable plasmodium
falciparum erythrocyte membrane protein-1 exhibits a conserved structure.
PLoS Pathog 4: e1000147. doi:10.1371/journal.ppat.1000147.
66. Hall N, Karras M, Raine JD, Carlton JM, Kooij TW, et al. (2005) A
comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic,
and proteomic analyses. Science 307: 82–86.
67. Cunningham DA, Jarra W, Koernig S, Fonager J, Fernandez-Reyes D, et al.
(2005) Host immunity modulates transcriptional changes in a multigene family
(yir) of rodent malaria. Mol Microbiol 58: 636–647.
68. del Portillo HA, Fernandez-Becerra C, Bowman S, Oliver K, Preuss MS, et al.
(2001) A superfamily of variant genes encoded in the subtelomeric region of
Plasmodium vivax. Nature 410: 839–842.
69. Carlton JM, Angiuoli SV, Suh BB, Kooij TW, Pertea M, et al. (2002) Genome
sequence and comparative analysis of the model rodent malaria parasite
Plasmodium yoelii yoelii. Nature 419: 512–519.
70. Janssen CS, Barrett MP, Turner CM, Phillips RS (2002) A large gene family for
putative variant antigens shared by human and rodent malaria parasites. Proc
Biol Sci 269: 431–436.
71. Janssen CS, Phillips RS, Turner CM, Barrett MP (2004) Plasmodium
interspersed repeats: the major multigene superfamily of malaria parasites.
Nucleic Acids Res 32: 5712–5720.
72. Fernandez-Becerra C, Pein O, de Oliveira TR, Yamamoto MM, Cassola AC,
et al. (2005) Variant proteins of Plasmodium vivax are not clonally expressed in
natural infections. Mol Microbiol 58: 648–658.
73. Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, et al. (2007) Lung
injury in vivax malaria: pathophysiological evidence for pulmonary vascular
sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis
195: 589–596.
74. Anstey NM, Russell B, Yeo TW, Price RN (2009) The pathophysiology of
vivax malaria. Trends Parasitol 25: 220–227.
75. Di GF, Raggi C, Birago C, Pizzi E, Lalle M, et al. (2008) Plasmodium lipid rafts
contain proteins implicated in vesicular trafficking and signalling as well as
members of the PIR superfamily, potentially implicated in host immune system
interactions. Proteomics 8: 2500–2513.
76. Sargeant TJ, Marti M, Caler E, Carlton JM, Simpson K, et al. (2006) Lineage-
specific expansion of proteins exported to erythrocytes in malaria parasites.
Genome Biol 7: R12.
77. Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, et al. (2006)
Oxidized phosphatidylserine-CD36 interactions play an essential role in
macrophage-dependent phagocytosis of apoptotic cells. J Exp Med 203:
2613–2625.
78. Eda S, Sherman IW (2002) Cytoadherence of malaria-infected red blood cells
involves exposure of phosphatidylserine. Cell Physiol Biochem 12: 373–384.
79. Manodori AB, Barabino GA, Lubin BH, Kuypers FA (2000) Adherence of
phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospon-
din. Blood 95: 1293–1300.
80. Curfs JH, van der Meer JW, Sauerwein RW, Eling WM (1990) Low dosages of
interleukin 1 protect mice against lethal cerebral malaria. J Exp Med 172:
1287–1291.
81. Hermsen CC, Mommers E, van de WT, Sauerwein RW, Eling WM (1998)
Convulsions due to increased permeability of the blood-brain barrier in
experimental cerebral malaria can be prevented by splenectomy or anti-T cell
treatment. J Infect Dis 178: 1225–1227.
82. Janse CJ, Boorsma EG, Ramesar J, Grobbee MJ, Mons B (1989) Host cell
specificity and schizogony of Plasmodium berghei under different in vitro
conditions. Int J Parasitol 19: 509–514.
83. Janse CJ, Boorsma EG, Ramesar J, van VP, van der MR, et al. (1989)
Plasmodium berghei: gametocyte production, DNA content, and chromosome-
size polymorphisms during asexual multiplication in vivo. Exp Parasitol 68:
274–282.
84. Sanni LA, Rae C, Maitland A, Stocker R, Hunt NH (2001) Is ischemia
involved in the pathogenesis of murine cerebral malaria? Am J Pathol 159:
1105–1112.
PLoS Pathogens | www.plospathogens.org 9 September 2010 | Volume 6 | Issue 9 | e100103285. Mitchell AJ, Hansen AM, Hee L, Ball HJ, Potter SM, et al. (2005) Early
cytokine production is associated with protection from murine cerebral
malaria. Infect Immun 73: 5645–5653.
86. Rogerson SJ, Tembenu R, Dobano C, Plitt S, Taylor TE, et al. (1999)
Cytoadherence characteristics of Plasmodium falciparum-infected erythrocytes
from Malawian children with severe and uncomplicated malaria. Am J Trop
Med Hyg 61: 467–472.
87. Traore B, Muanza K, Looareesuwan S, Supavej S, Khusmith S, et al. (2000)
Cytoadherence characteristics of Plasmodium falciparum isolates in Thailand
using an in vitro human lung endothelial cells model. Am J Trop Med Hyg 62:
38–44.
88. Cortes A, Mellombo M, Mgone CS, Beck HP, Reeder JC, et al. (2005)
Adhesion of Plasmodium falciparum-infected red blood cells to CD36 under
flow is enhanced by the cerebral malaria-protective trait South-East Asian
ovalocytosis. Mol Biochem Parasitol 142: 252–257.
89. Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, et al. (2000)
Malaria susceptibility and CD36 mutation. Nature 405: 1015–1016.
90. Roberts DJ, Pain A, Kai O, Kortok M, Marsh K (2000) Autoagglutination of
malaria-infected red blood cells and malaria severity. Lancet 355: 1427–1428.
91. Cholera R, Brittain NJ, Gillrie MR, Lopera-Mesa TM, Diakite SA, et al. (2008)
Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes
containing sickle hemoglobin. Proc Natl Acad Sci U S A 105: 991–996.
92. Wassmer SC, Lepolard C, Traore B, Pouvelle B, Gysin J, et al. (2004) Platelets
reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated
endothelial cells. J Infect Dis 189: 180–189.
93. Grau GE, Mackenzie CD, Carr RA, Redard M, Pizzolato G, et al. (2003)
Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria.
J Infect Dis 187: 461–466.
94. McGilvray ID, Serghides L, Kapus A, Rotstein OD, Kain KC (2000)
Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-
parasitized erythrocytes: a role for CD36 in malarial clearance. Blood 96:
3231–3240.
95. Serghides L, Kain KC (2001) Peroxisome proliferator-activated receptor
gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of
Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced
TNF-alpha secretion by monocytes/macrophages. J Immunol 166: 6742–6748.
96. Cunha-Rodrigues M, Portugal S, Febbraio M, Mota MM (2007) Bone marrow
chimeric mice reveal a dual role for CD36 in Plasmodium berghei ANKA
infection. Malar J 6: 32.
97. Bauer PR, van der Heyde HC, Sun G, Specian RD, Granger DN (2002)
Regulation of endothelial cell adhesion molecule expression in an experimental
model of cerebral malaria. Microcirculation 9: 463–470.
98. Li J, Chang WL, Sun G, Chen HL, Specian RD, et al. (2003) Intercellular
adhesion molecule 1 is important for the development of severe experimental
malaria but is not required for leukocyte adhesion in the brain. J Investig Med
51: 128–140.
99. Graewe S, Retzlaff S, Struck N, Janse CJ, Heussler VT (2009) Going live: a
comparative analysis of the suitability of the RFP derivatives RedStar, mCherry
and tdTomato for intravital and in vitro live imaging of Plasmodium parasites.
Biotechnol J 4: 895–902.
100. Zarbock A, Ley K (2009) New insights into leukocyte recruitment by intravital
microscopy. Curr Top Microbiol Immunol 334: 129–152.
101. Svoboda K, Yasuda R (2006) Principles of two-photon excitation microscopy
and its applications to neuroscience. Neuron 50: 823–839.
102. Diaspro A, Chirico G, Collini M (2005) Two-photon fluorescence excitation
and related techniques in biological microscopy. Q Rev Biophys 38: 97–166.
103. Dufresne AT, Gromeier M (2004) A nonpolio enterovirus with respiratory
tropism causes poliomyelitis in intercellular adhesion molecule 1 transgenic
mice. Proc Natl Acad Sci U S A 101: 13636–13641.
104. Randall LM, Amante FH, Zhou Y, Stanley AC, Haque A, et al. (2008) Cutting
edge: selective blockade of LIGHT-lymphotoxin beta receptor signaling
protects mice from experimental cerebral malaria caused by Plasmodium
berghei ANKA. J Immunol 181: 7458–7462.
105. Seydel KB, Milner DA, Jr., Kamiza SB, Molyneux ME, Taylor TE (2006) The
distribution and intensity of parasite sequestration in comatose Malawian
children. J Infect Dis 194: 208–5.
106. Silamut K, Phu NH, Whitty C, Turner GD, Louwrier K, et al. (1999) A
quantitative analysis of the microvascular sequestration of malaria parasites in
the human brain. Am J Pathol 155: 395–410.
107. Chakravorty SJ, Hughes KR, Craig AG (2008) Host response to cytoadherence
in Plasmodium falciparum. Biochem Soc Trans 36: 221–228.
108. Scherf A, Lopez-Rubio JJ, Riviere L (2008) Antigenic variation in Plasmodium
falciparum. Annu Rev Microbiol 62: 445–470.
109. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K,
et al. (2005) Estimation of the total parasite biomass in acute falciparum
malaria from plasma PfHRP2. PLoS Med 2: e204. doi:10.1371/journal.
pmed.0020204.
110. Pongponratn E, Turner GD, Day NP, Phu NH, Simpson JA, et al. (2003) An
ultrastructural study of the brain in fatal Plasmodium falciparum malaria.
Am J Trop Med Hyg 69: 345–359.
111. Pasternak ND, Dzikowski R (2009) PfEMP1: an antigen that plays a key role in
the pathogenicity and immune evasion of the malaria parasite Plasmodium
falciparum. Int J Biochem Cell Biol 41: 1463–1466.
112. Warimwe GM, Keane TM, Fegan G, Musyoki JN, Newton CR, et al. (2009)
Plasmodium falciparum var gene expression is modified by host immunity.
Proc Natl Acad Sci U S A 106: 21801–21806.
113. Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L, et al. (2004)
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria.
J Exp Med 200: 1197–1203.
114. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, et al. (2004)
Differentiating the pathologies of cerebral malaria by postmortem parasite
counts. Nat Med 10: 143–145.
115. Fried M, Duffy PE (1996) Adherence of Plasmodium falciparum to chondroitin
sulfate A in the human placenta. Science 272: 1502–1504.
PLoS Pathogens | www.plospathogens.org 10 September 2010 | Volume 6 | Issue 9 | e1001032